J Grosset

15.5k total citations
258 papers, 10.5k citations indexed

About

J Grosset is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, J Grosset has authored 258 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Infectious Diseases, 153 papers in Epidemiology and 50 papers in Surgery. Recurrent topics in J Grosset's work include Tuberculosis Research and Epidemiology (175 papers), Mycobacterium research and diagnosis (130 papers) and Cancer therapeutics and mechanisms (40 papers). J Grosset is often cited by papers focused on Tuberculosis Research and Epidemiology (175 papers), Mycobacterium research and diagnosis (130 papers) and Cancer therapeutics and mechanisms (40 papers). J Grosset collaborates with scholars based in France, United States and South Africa. J Grosset's co-authors include Eric L. Nuermberger, William R. Bishai, C. Truffot-Pernot, Sandeep Tyagi, Deepak V. Almeida, Kathy N. Williams, Ian M. Rosenthal, Botao Ji, Nacer Lounis and Tetsuyuki Yoshimatsu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Genetics.

In The Last Decade

J Grosset

242 papers receiving 9.9k citations

Peers

Countries citing papers authored by J Grosset

Since Specialization

Citations

This map shows the geographic impact of J Grosset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Grosset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Grosset more than expected).

Fields of papers citing papers by J Grosset

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Grosset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Grosset. The network helps show where J Grosset may publish in the future.

Co-authorship network of co-authors of J Grosset

This figure shows the co-authorship network connecting the top 25 collaborators of J Grosset. A scholar is included among the top collaborators of J Grosset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Grosset. J Grosset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease 2018 ·Antimicrobial Agents and Chemotherapy ·Till F. Omansen, Deepak V. Almeida, Paul J. Converse, Si-Yang Li, Jin Lee, Ymkje Stienstra, Tjip S. van der Werf, J Grosset, Eric L. Nuermberger	13
2	Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis 2015 ·Proceedings of the National Academy of Sciences ·Sandeep Tyagi, Nicole C. Ammerman, Si-Yang Li, John Adamson, Paul J. Converse, Rosemary V. Swanson, Deepak V. Almeida, J Grosset	91
3	Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models 2011 ·Journal of Antimicrobial Chemotherapy ·Zahoor Ahmad, Mostafa Fraig, Michael L. Pinn, Sandeep Tyagi, Eric L. Nuermberger, J Grosset, Petros C. Karakousis	19
4	Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig 2010 ·Journal of Antimicrobial Chemotherapy ·Zahoor Ahmad, Eric Nuermberger, Rokeya Tasneen, Michael L. Pinn, Kathy N. Williams, Charles A. Peloquin, J Grosset, Petros C. Karakousis	42
5	Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis 2008 ·Antimicrobial Agents and Chemotherapy ·Rokeya Tasneen, Sandeep Tyagi, Kathy N. Williams, J Grosset, Eric L. Nuermberger	77
6	Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model 2008 ·Antimicrobial Agents and Chemotherapy ·Kathy N. Williams, C. Kendall Stover, Tong Zhu, Rokeya Tasneen, Sandeep Tyagi, J Grosset, Eric L. Nuermberger	160
7	Pharmacokinetics of Rifampicin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection in Ghana 2008 ·46th Annual Meeting ·Jan‐Willem C. Alffenaar, Willemien A. Nienhuis, Femke de Velde, (unknown), A. Mireille A. Wessels, Deepak V. Almeida, J Grosset, Ohene Adjei, Donald R. A. Uges, Tjip S. van der Werf	1
8	In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis 2007 ·Antimicrobial Agents and Chemotherapy ·Deepak V. Almeida, Eric Nuermberger, Sandeep Tyagi, William R. Bishai, J Grosset	31
9	Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis 2005 ·American Journal of Respiratory and Critical Care Medicine ·Ian M. Rosenthal, Kathy N. Williams, Sandeep Tyagi, Andrew Vernon, Charles A. Peloquin, William R. Bishai, J Grosset, Eric Nuermberger	42
10	Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model 2005 ·American Journal of Respiratory and Critical Care Medicine ·Eric Nuermberger, Sandeep Tyagi, Kathy N. Williams, Ian M. Rosenthal, William R. Bishai, J Grosset	58
11	Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis 2003 ·American Journal of Respiratory and Critical Care Medicine ·Eric L. Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi, Richard O’Brien, Andrew Vernon, Richard E. Chaisson, William R. Bishai, J Grosset	242
12	Épidémiologie mondiale de la tuberculose et de la résistance aux antibiotiques antituberculeux 2002 ·J Grosset, Lejla Žunić, (unknown)	3
13	A method for rapid detection of rifampicin-resistant isolates ofMycobacterium leprae 2001 ·Leprosy Review ·Nadine Honoré, Paul Roche, J Grosset, Stewart T. Cole	15
14	Outcome of Multi-drug-resistant Tuberculosis in France: A Nationwide Case-Control Study 1999 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), J. Robert, Vincent Jarlier, J Grosset	75
15	The challenge of tuberculosis: statements on global control and prevention 1995 ·The Lancet ·Donald A. Enarson, J Grosset, Alwyn Mwinga, Earl S. Hershfield, Richard O’Brien, Stewart T. Cole, Lee B. Reichman	34
16	Preventive Therapy of Tuberculosis with Rifapentine in Immunocompetent and Nude Mice 1994 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Botao Ji, C. Truffot-Pernot, Richard O’Brien, Mario Raviǵlione, J Grosset	32
17	Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? 1992 ·(unknown), J Grosset, C. Hupin, D. L. LEIKER, Dileep N. Lobo, J M Mehta, (unknown), R Urbanczik	1
18	Characteristics of the multiplication of dapsone-resistant strains of Mycobacterium leprae in mice 1988 ·Leprosy Review ·(unknown), M. Joseph Colston, G.A. Ellard, (unknown), J Grosset, (unknown), (unknown), (unknown), (unknown), D. L. LEIKER, L Lévy, S. K. Noordeen, SR Pattyn, J. M. H. Pearson, (unknown), (unknown), (unknown), Joachim K. Seydel, Charles C. Shepard, Michael F. Waters	0
19	Experimental data on short-course chemotherapy 1978 ·J Grosset	2
20	[INCIDENCE AND CHARACTERISTICS OF PRIMARY RESISTANCE IN 2144 CASES OF UNTREATED PULMONARY TUBERCULOSIS FROM DIFFERENT REGIONS OF FRANCE. (PRELIMINARY REPORT OF THE CENTRE D'ETUDE SUR LA R'ESISTANCE PRIMAIRE)]. 1964 ·PubMed ·G Canetti, (unknown), (unknown), J Grosset, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact